Merluzzi suggests that NfL may be more sensitive to subclinical cognitive decline compared to other proposed biomarkers of neurodegeneration, whereas neurogranin and t-tau are not [108].The rate of change of serum NfL can distinguish mutation carriers from non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels (16.2 versus 6.8 years before the estimated onset of AD symptom) [41] and is correlated with EYO (estimated year of onset) and multiple cognitive and imaging measures [109]. The gene discussed is NEFL; the disease is Alzheimer disease.